A recombinant envelope protein vaccine against West Nile virus

Michel Ledizet, Kalipada Kar, Harald G. Foellmer, Tian Wang, Sandra L. Bushmich, John F. Anderson, Erol Fikrig, Raymond A. Koski

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

West Nile (WN) virus is a flavivirus that first appeared in North America in 1999. Since then, more than 600 human deaths and 22,000 equine infections have been attributed to the virus in the United States. We expressed a truncated form of WN virus envelope (E) protein in Drosophila S2 cells. This soluble recombinant E protein was recognized by antibodies from naturally infected horses, indicating that it contains native epitopes. Mice and horses produced high-titer antibodies when immunized with recombinant E protein combined with aluminum hydroxide. Immunized mice were resistant to challenge with a lethal viral dose. Sera from immunized horses, administered to naïve mice, conferred resistance against a lethal WN viral challenge. In addition, sera of immunized horses neutralized West Nile virus in vitro, as demonstrated by plaque reduction assays. This recombinant form of E protein, combined with aluminum hydroxide, is a candidate vaccine that may protect humans and horses against WN virus infections.

Original languageEnglish (US)
Pages (from-to)3915-3924
Number of pages10
JournalVaccine
Volume23
Issue number30
DOIs
StatePublished - Jun 10 2005
Externally publishedYes

Fingerprint

West Nile Virus Vaccines
West Nile virus
Recombinant Proteins
Horses
vaccines
horses
Aluminum Hydroxide
aluminum hydroxide
proteins
mice
Viral Envelope Proteins
Flavivirus
antibodies
Antibodies
Virus Diseases
North America
Serum
infection
epitopes
Drosophila

Keywords

  • Envelope protein
  • Vaccine
  • West Nile virus

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Ledizet, M., Kar, K., Foellmer, H. G., Wang, T., Bushmich, S. L., Anderson, J. F., ... Koski, R. A. (2005). A recombinant envelope protein vaccine against West Nile virus. Vaccine, 23(30), 3915-3924. https://doi.org/10.1016/j.vaccine.2005.03.006

A recombinant envelope protein vaccine against West Nile virus. / Ledizet, Michel; Kar, Kalipada; Foellmer, Harald G.; Wang, Tian; Bushmich, Sandra L.; Anderson, John F.; Fikrig, Erol; Koski, Raymond A.

In: Vaccine, Vol. 23, No. 30, 10.06.2005, p. 3915-3924.

Research output: Contribution to journalArticle

Ledizet, M, Kar, K, Foellmer, HG, Wang, T, Bushmich, SL, Anderson, JF, Fikrig, E & Koski, RA 2005, 'A recombinant envelope protein vaccine against West Nile virus', Vaccine, vol. 23, no. 30, pp. 3915-3924. https://doi.org/10.1016/j.vaccine.2005.03.006
Ledizet M, Kar K, Foellmer HG, Wang T, Bushmich SL, Anderson JF et al. A recombinant envelope protein vaccine against West Nile virus. Vaccine. 2005 Jun 10;23(30):3915-3924. https://doi.org/10.1016/j.vaccine.2005.03.006
Ledizet, Michel ; Kar, Kalipada ; Foellmer, Harald G. ; Wang, Tian ; Bushmich, Sandra L. ; Anderson, John F. ; Fikrig, Erol ; Koski, Raymond A. / A recombinant envelope protein vaccine against West Nile virus. In: Vaccine. 2005 ; Vol. 23, No. 30. pp. 3915-3924.
@article{b61c8072bbf842aa9bc63a97c3fc2c2e,
title = "A recombinant envelope protein vaccine against West Nile virus",
abstract = "West Nile (WN) virus is a flavivirus that first appeared in North America in 1999. Since then, more than 600 human deaths and 22,000 equine infections have been attributed to the virus in the United States. We expressed a truncated form of WN virus envelope (E) protein in Drosophila S2 cells. This soluble recombinant E protein was recognized by antibodies from naturally infected horses, indicating that it contains native epitopes. Mice and horses produced high-titer antibodies when immunized with recombinant E protein combined with aluminum hydroxide. Immunized mice were resistant to challenge with a lethal viral dose. Sera from immunized horses, administered to na{\"i}ve mice, conferred resistance against a lethal WN viral challenge. In addition, sera of immunized horses neutralized West Nile virus in vitro, as demonstrated by plaque reduction assays. This recombinant form of E protein, combined with aluminum hydroxide, is a candidate vaccine that may protect humans and horses against WN virus infections.",
keywords = "Envelope protein, Vaccine, West Nile virus",
author = "Michel Ledizet and Kalipada Kar and Foellmer, {Harald G.} and Tian Wang and Bushmich, {Sandra L.} and Anderson, {John F.} and Erol Fikrig and Koski, {Raymond A.}",
year = "2005",
month = "6",
day = "10",
doi = "10.1016/j.vaccine.2005.03.006",
language = "English (US)",
volume = "23",
pages = "3915--3924",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "30",

}

TY - JOUR

T1 - A recombinant envelope protein vaccine against West Nile virus

AU - Ledizet, Michel

AU - Kar, Kalipada

AU - Foellmer, Harald G.

AU - Wang, Tian

AU - Bushmich, Sandra L.

AU - Anderson, John F.

AU - Fikrig, Erol

AU - Koski, Raymond A.

PY - 2005/6/10

Y1 - 2005/6/10

N2 - West Nile (WN) virus is a flavivirus that first appeared in North America in 1999. Since then, more than 600 human deaths and 22,000 equine infections have been attributed to the virus in the United States. We expressed a truncated form of WN virus envelope (E) protein in Drosophila S2 cells. This soluble recombinant E protein was recognized by antibodies from naturally infected horses, indicating that it contains native epitopes. Mice and horses produced high-titer antibodies when immunized with recombinant E protein combined with aluminum hydroxide. Immunized mice were resistant to challenge with a lethal viral dose. Sera from immunized horses, administered to naïve mice, conferred resistance against a lethal WN viral challenge. In addition, sera of immunized horses neutralized West Nile virus in vitro, as demonstrated by plaque reduction assays. This recombinant form of E protein, combined with aluminum hydroxide, is a candidate vaccine that may protect humans and horses against WN virus infections.

AB - West Nile (WN) virus is a flavivirus that first appeared in North America in 1999. Since then, more than 600 human deaths and 22,000 equine infections have been attributed to the virus in the United States. We expressed a truncated form of WN virus envelope (E) protein in Drosophila S2 cells. This soluble recombinant E protein was recognized by antibodies from naturally infected horses, indicating that it contains native epitopes. Mice and horses produced high-titer antibodies when immunized with recombinant E protein combined with aluminum hydroxide. Immunized mice were resistant to challenge with a lethal viral dose. Sera from immunized horses, administered to naïve mice, conferred resistance against a lethal WN viral challenge. In addition, sera of immunized horses neutralized West Nile virus in vitro, as demonstrated by plaque reduction assays. This recombinant form of E protein, combined with aluminum hydroxide, is a candidate vaccine that may protect humans and horses against WN virus infections.

KW - Envelope protein

KW - Vaccine

KW - West Nile virus

UR - http://www.scopus.com/inward/record.url?scp=19444369938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19444369938&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.03.006

DO - 10.1016/j.vaccine.2005.03.006

M3 - Article

VL - 23

SP - 3915

EP - 3924

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 30

ER -